Sientra, Inc. (SIEN): Price and Financial Metrics

Sientra, Inc. (SIEN): $1.00

-0.05 (-4.77%)

POWR Rating

Component Grades














  • SIEN scores best on the Growth dimension, with a Growth rank ahead of 88.85% of US stocks.
  • The strongest trend for SIEN is in Growth, which has been heading up over the past 179 days.
  • SIEN ranks lowest in Sentiment; there it ranks in the 4th percentile.

SIEN Stock Summary

  • SIEN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 0.09% of US stocks.
  • In terms of volatility of its share price, SIEN is more volatile than 92.44% of stocks we're observing.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SIEN comes in at -31.88% -- higher than that of only 12.43% of stocks in our set.
  • Stocks that are quantitatively similar to SIEN, based on their financial statements, market capitalization, and price volatility, are LJPC, PUBM, OMCL, UPST, and PIPR.
  • Visit SIEN's SEC page to see the company's official filings. To visit the company's web site, go to

SIEN Valuation Summary

  • In comparison to the median Healthcare stock, SIEN's price/earnings ratio is 109.59% lower, now standing at -3.5.
  • SIEN's price/sales ratio has moved down 2.3 over the prior 83 months.
  • SIEN's price/earnings ratio has moved up 19.8 over the prior 83 months.

Below are key valuation metrics over time for SIEN.

Stock Date P/S P/B P/E EV/EBIT
SIEN 2021-08-31 4.1 -11.4 -3.5 -3.6
SIEN 2021-08-30 4.1 -11.3 -3.4 -3.6
SIEN 2021-08-27 4.3 -11.7 -3.6 -3.7
SIEN 2021-08-26 4.3 -11.9 -3.6 -3.8
SIEN 2021-08-25 4.4 -12.1 -3.7 -3.8
SIEN 2021-08-24 4.2 -11.6 -3.5 -3.7

SIEN Growth Metrics

    Its 2 year net cashflow from operations growth rate is now at -77.37%.
  • Its 3 year cash and equivalents growth rate is now at -33.73%.
  • Its year over year price growth rate is now at 179.09%.
Over the past 33 months, SIEN's revenue has gone up $17,477,000.

The table below shows SIEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 85.603 -36.94 -67.651
2021-06-30 85.2 -28.63 -101.882
2021-03-31 77.545 -45.605 -116.025
2020-12-31 71.241 -60.127 -89.947
2020-09-30 71.807 -66.269 -88.957
2020-06-30 75.002 -85.002 -105.569

SIEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SIEN has a Quality Grade of C, ranking ahead of 28.53% of graded US stocks.
  • SIEN's asset turnover comes in at 0.463 -- ranking 103rd of 186 Medical Equipment stocks.
  • NAOV, NUWE, and ISR are the stocks whose asset turnover ratios are most correlated with SIEN.

The table below shows SIEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.463 0.534 -1.000
2021-03-31 0.425 0.530 -1.073
2020-12-31 0.378 0.547 -0.825
2020-09-30 0.363 0.586 -0.881
2020-06-30 0.360 0.586 -1.192
2020-03-31 0.372 0.599 -1.612

SIEN Price Target

For more insight on analysts targets of SIEN, see our SIEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $11.29 Average Broker Recommendation 1.12 (Strong Buy)

SIEN Stock Price Chart Interactive Chart >

Price chart for SIEN

SIEN Price/Volume Stats

Current price $1.00 52-week high $9.14
Prev. close $1.05 52-week low $0.97
Day low $0.97 Volume 3,788,728
Day high $1.11 Avg. volume 650,474
50-day MA $1.72 Dividend yield N/A
200-day MA $3.74 Market Cap 62.63M

Sientra, Inc. (SIEN) Company Bio

Sientra Inc. develops and sells medical aesthetics products to plastic surgeons in the United States. The company was founded in 2003 and is based in Santa Barbara, California.

SIEN Latest News Stream

Event/Time News Detail
Loading, please wait...

SIEN Latest Social Stream

Loading social stream, please wait...

View Full SIEN Social Stream

Latest SIEN News From Around the Web

Below are the latest news stories about Sientra Inc that investors may wish to consider to help them evaluate SIEN as an investment opportunity.

Health Check: How Prudently Does Sientra (NASDAQ:SIEN) Use Debt?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | February 8, 2022

Salomon & Ludwin, LLC Buys Eli Lilly and Co, AbbVie Inc, Abbott Laboratories, Sells ...

Investment company Salomon & Ludwin, LLC (Current Portfolio) buys Eli Lilly and Co, AbbVie Inc, Abbott Laboratories, Hasbro Inc, PowerShares QQQ Trust Ser 1, sells Vanguard S&P 500 ETF, Vanguard Short-Term Corporate Bond ETF, Wells Fargo, Vanguard Small Cap ETF, Vanguard Large Cap ETF during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Salomon & Ludwin, LLC.

Yahoo | February 5, 2022

Sientra (SIEN) Receives a Buy from Colliers Securities

E ratio of -2.31.

Brian Anderson on TipRanks | January 10, 2022

Sientra Reports Record Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenues

Estimates highest ever Breast Products yearly revenue of $80-$81 million representing 46%-47% full year growth Results driven by continued strong demand for Sientra Breast Products and commercial execution SANTA BARBARA, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company uniquely focused on plastic surgeons, today announced preliminary unaudited financial results for the fourth quarter and full year ended December 31,

Yahoo | January 10, 2022

Sientra: Shares Could More Than Triple From Here, Says Analyst

The U.S. plastic surgery market is thought to be worth around $13 billion. With its new acquisition, Sientra (SIEN) will be hoping to improve its positioning in this lucrative space. On Wednesday, the medical aesthetics company announced it plans on acquiring AuraGen’s fat grafting technology for $17.5 million. This consists of $13.5 million in stock, $1 million in cash when the deal closes, and another $3 million in cash in 12 months time. There’s a potential $8.5 million earnout too, subject to the achievement of certain clinical endpoints. While the product has yet to hit the market, it’s already FDA-approved and Sientra plans a full commercial launch in January 2023.

Marty Shtrubel on TipRanks | January 6, 2022

Read More 'SIEN' Stories Here

SIEN Price Returns

1-mo -28.06%
3-mo -64.79%
6-mo -75.70%
1-year -85.82%
3-year -84.66%
5-year -86.52%
YTD -72.75%
2021 -5.66%
2020 -56.49%
2019 -29.66%
2018 -9.60%
2017 65.02%

Continue Researching SIEN

Here are a few links from around the web to help you further your research on Sientra Inc's stock as an investment opportunity:

Sientra Inc (SIEN) Stock Price | Nasdaq
Sientra Inc (SIEN) Stock Quote, History and News - Yahoo Finance
Sientra Inc (SIEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6474 seconds.